Original articleAlimentary tractA Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Section snippets
Methods
The study (A3921043, ClinicalTrials.gov NCT00615199) was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines established by the International Conference on Harmonisation. The protocol was approved by the Institutional Review Board at each center. All patients provided written informed consent. The study investigators were responsible for adhering to the study procedures described in the protocol. The study was patient-, investigator-, and
Patient Disposition and Demographics
In total, 236 patients were screened; 139 (58.9%) patients were randomized to receive tofacitinib 1 (n = 36), 5 (n = 34), or 15 mg twice daily (n = 35), or placebo twice daily (n = 34); 126 (90.6%) patients completed the study (Supplementary Figure 1). One patient with a baseline CDAI score of less than 150 from the 5-mg twice-daily group was excluded from all efficacy analyses. Baseline demographic characteristics were similar between groups (Table 1). Steroids (meprednisone, prednisone,
Discussion
In this 4-week, phase 2 trial in patients with moderate-to-severe active Crohn’s disease, a proportion of whom had failed conventional therapy, tofacitinib did not show efficacy in the induction of a clinical response, as measured by Response-70/-100 or clinical remission rates; however, placebo response and remission rates were greater than expected. Tofacitinib 15 mg twice daily reduced CRP and fecal calprotectin concentrations, and numeric improvements from baseline in IBDQ score were
Conclusions
In conclusion, patients with moderate-to-severe active Crohn’s disease treated with tofacitinib were not more likely to achieve clinical response or clinical remission vs those receiving placebo; however, the placebo response and remission rates were unexpectedly high. The reductions in CRP and fecal calprotectin values in the tofacitinib 15-mg twice-daily group suggest biologic activity. Further studies are needed to determine whether tofacitinib is effective for the treatment of Crohn’s
Acknowledgements
The authors would like to thank the patients who were involved in this study, and the A3921043 investigators and study team.
References (16)
- et al.
Crohn's disease
Lancet
(2012) - et al.
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
Gastroenterology
(2006) - et al.
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year
Am J Transplant
(2012) - et al.
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study
Gastroenterology
(1976) - et al.
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group
Gastroenterology
(1994) - et al.
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease
Gastroenterology
(2004) - et al.
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
Gastroenterology
(2006) - et al.
A qualitive analysis of kinase inhibitor selectivity
Nat Biotechnol
(2008)
Cited by (260)
Recent advances in the treatment of IBD: Targets, mechanisms and related therapies
2023, Cytokine and Growth Factor ReviewsSelective JAK1 inhibitors for the treatment of inflammatory bowel disease
2023, Pharmacology and TherapeuticsThe role of filgotinib in ulcerative colitis and Crohn's disease
2024, ImmunotherapyUpdate for surgeons on novel induction treatments for acute severe inflammatory bowel disease associated colitis
2024, ANZ Journal of SurgeryAre All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?
2023, Gastroenterology and HepatologyResearch trends of Janus Kinase inhibitors: a bibliometric and visualized study from 2012 to 2023
2023, European Review for Medical and Pharmacological Sciences
Conflicts of interest The authors disclose the following: William Sandborn has received consulting fees from Abbott, ActoGeniX NV, AGI Therapeutics, Inc, Alba Therapeutics Corp, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas, Athersys, Inc, Atlantic Healthcare, Ltd, Aptalis, BioBalance Corp, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, EnGene, Inc, Eli Lilly, Enteromedics, Exagen, Diagnostics, Inc, Ferring Pharmaceuticals, Flexio Therapeutics, Inc, Funxional Therapeutics, Ltd, Genzyme Corp, Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen Pharmaceutical Research & Development, LLC, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Lycera Corp, Meda Pharmaceuticals, Merck Research Laboratories, Merck Serono, Millennium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Inc, PDL Biopharma, Pfizer Inc, Procter and Gamble, Prometheus Laboratories, ProtAb, Ltd, Purgenesis Technologies, Inc, Relypsa, Inc, Roche, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus, Schering Plough, Shire Pharmaceuticals, Sigmoid Pharma, Ltd, Sirtris Pharmaceuticals, SLA Pharma UK, Ltd, Targacept, Teva Pharmaceuticals, Therakos, Tilliotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics, Ltd, Warner Chilcott UK, Ltd, and Wyeth; has received research grants from Abbott, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, LLC, Millennium Pharmaceuticals, Novartis, Pfizer Inc, Procter and Gamble, Shire Pharmaceuticals, and UCB Pharma; has received payments for lectures and speakers bureau fees from Abbott, Bristol-Myers Squibb, and Janssen Pharmaceutical Research & Development, LLC; and holds stock/stock options in Enteromedics. Subrata Ghosh has received consulting fees from Abbott, Pfizer Inc, Merck, Shire, Centocor, and BMS; has received research grants from Merck and Abbott; has received payment for lectures from Abbott, Merck, Shire, Millennium, Centocor, and Ferring; and has received payment for the development of an educational presentation from Abbott. Julian Panes has received speaker fees from AbbVie, MSD, Shire Pharmaceuticals, and UCB; has acted as a scientific consultant for AbbVie, Bristol-Myers Squibb, Ferring, MSD, Novartis, Pfizer Inc, Shire Pharmaceuticals, Tygenics, and UCB; and has received research grants from AbbVie and MSD. Ivana Vranic, Wenjin Wang, and Wojciech Niezychowski are employees of, and hold stock/stock options in, Pfizer Inc.
Funding This study was sponsored by Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications, funded by Pfizer Inc.